IndiaMART InterMESH Limited Announces 12M FY24 (Full Year) and Q4FY24 (Fourth Quarter) Ending March 31, 2024 - Results-GJEPC innovNXT I Forty Under 40 - Next Gen Leadership Summit Witnesses Young Leaders Transforming The Business Landscape and Driving Growth-TBO TEK LIMITED IPO OPENS ON 8 May, 2024 PRICE BAND SET AT Rs. 875 TO 920 PER EQUITY SHARE-आधार हाउसिंग फाइनैंस लिमिटेड का आईपीओ 8-10 मई तक, 3,000 करोड़ जुटाएगी-Airbnb introduces Icons— Bollywood Star Jahnvi Kapoor opens the door to her legendary, never-before-seen family home in Chennai-AADHAR HOUSING FINANCE LIMITED IPO OPENS ON MAY 8, 2024 PRICE BAND SET AT Rs. 300 TO 315 PER EQUITY SHARE-महाराष्ट्र दिवस पर कालबादेवी में ओशो समारोह 'ओशो के अनुज डॉक्टर स्वामी शैलेंद्र सरस्वती' और 'मां अमृत प्रियाजी' की उपस्थिति में ओशो का ध्यान प्रयोग और प्रवचन होगा-Dr L H Hiranandani Hospital Launches Advanced Robotic System for Knee Replacement Surgeries-OSHO Meditation and Discourse to be hosted on 1st May at Sojat Swarna Bhawan, Kalbadevi, Mumbai In the gracious presence of Dr. Swami Shailendra Saraswati (OSHO’S Anuj) and Maa Amrut Priya-Lilavati Kirtilal Mehta Medical Trust Board Has Exposed A Major Financial Fraud Amounting Around Rs. 500 Crores, Making It A Serious Medical Scam

Kotak Mahindra Capital Company Associates with Ignite Life Science Foundation for Research in Antimicrobial Resistance

Kotak Mahindra Capital Company Ltd

MUMBAI, 26th JUNE, 2023 (GPN): Under its corporate social responsibility (CSR) initiative, Kotak Mahindra Capital Company Ltd (“KMCC” / “Kotak Investment Banking”) today announced its association with Ignite Life Science Foundation (ILSF) for supporting research in the area of Antimicrobial Resistance (AMR).

The Bengaluru-based not-for-profit foundation, ILSF aims to leverage scientific discoveries for social good. The COVID-19 pandemic unmasked the growing problem of AMR in India, which can’t be solved through expensive antimicrobial drugs that are being developed. The country needs cheaper and more effective solutions that can minimise antimicrobial drug usage in all environments, including in agriculture. Solutions for AMR can come from new knowledge about resistance mechanisms in microorganisms and diagnostic methods to rapidly identify the organism causing an infection.

Ramesh Srinivasan, MD & CEO, Kotak Mahindra Capital Company said, “Our CSR Project on Healthcare includes preventive healthcare and sanitation. We are pleased to associate with Ignite Life Science Foundation to provide CSR funding for research in the area of Antimicrobial Resistance. We believe that our CSR project is likely to produce outcomes that are of immense benefit, given the scale and importance of these problems for human health.”

Dr. T. S. Balganesh, President of GangaGen Biotechnologies Pvt Ltd and a member of the Scientific Advisory Board of Ignite Life Science Foundation said, “Antimicrobial Resistance is on the verge of upsetting all the gains that we have made with modern medicine. Novel therapeutics aimed to address this global and local problem is urgently needed as a part of the ‘one health’ concept for sustaining our race. AMR is a priority area under India’s G-20 presidency. Increasing our collective effort through funding for research, awareness and stewardship will surely make an impact towards combating this potential ‘pandemic’.”

KMCC’s CSR Project will act as a triaging and a support mechanism to ensure that good ideas in the field of AMR thrive to a stage where they can be worked on by industry partners or collaborators.

Kotak Karma is the Corporate Social Responsibility (CSR) identity of Kotak Mahindra Group.Ends

About the Author

Sachin Murdeshwar
Sachin Murdeshwar is a Sr.Journalist and Columnist in several Mainline Newspapers and Portals.He is an ardent traveller and likes to explore destinations to the core.

Be the first to comment on "Kotak Mahindra Capital Company Associates with Ignite Life Science Foundation for Research in Antimicrobial Resistance"

Leave a comment

Your email address will not be published.


*